Circular CCR5 peptide conjugates and uses thereof (WO2008074895). (Q39477959)

12 September 2017

title

Circular CCR5 peptide conjugates and uses thereof (WO2008074895). (English)

1 reference

12 September 2017

Maja A Sommerfelt

1

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Therapeutic Patents

12 September 2017

published in

1 reference

12 September 2017

volume

19

1 reference

12 September 2017

issue

9

1 reference

12 September 2017

page(s)

1323-1328

1 reference

Identification of a major co-receptor for primary isolates of HIV-1

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Virus-like particles: flexible platforms for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Immunodrugs: therapeutic VLP-based vaccines for chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Biology of CCR5 and its role in HIV infection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Immunogenicity of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficiency virus or HIV infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

The second extracellular loop of CCR5 is the major determinant of ligand specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Safety concerns about CCR5 as an antiviral target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

Use of chemokine receptors by poxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967682

10.1517/13543770902967682

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference